{3',5'-Dimethyl-4'-[3-(3-methyl-isoxazol-5-yl)-propoxy]-biphenyl-4-yl}-dimethyl-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {3',5'-Dimethyl-4'-[3-(3-methyl-isoxazol-5-yl)-propoxy]-biphenyl-4-yl}-dimethyl-amine
• 英文别名: 4-[3,5-dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl]-N,N-dimethyl-aniline；4-[3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl]-N,N-dimethylaniline
• 化学式: C₂₃H₂₈N₂O₂
• 分子量: 364.488
• InChiKey: USAFZFPFFJBHGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  38.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-碘-N,N-二甲基苯胺 、 3-<3-<2,6-dimethyl-4-(tributylstannyl)phenoxy>propyl>-3-methylisoxazole 在 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以11%的产率得到{3',5'-Dimethyl-4'-[3-(3-methyl-isoxazol-5-yl)-propoxy]-biphenyl-4-yl}-dimethyl-amine
  参考文献：
  名称：

  [(Biaryloxy)alkyl]isoxazoles: Picornavirus Inhibitors

  摘要：

  A series of biphenyl analogs, 6, of 5-[5-(2,6-dichloro-5-oxazolylphenoxy)pentyl]-3-methylisoxazole (2) have been synthesized and tested in vitro against 10 human rhinovirus serotypes in a TCID50 assay. The most potent compound in the series 6s, 3-[3-[2,6-dimethyl-4-(4-fluorophenyl)phenoxy]propyl]-3-methylisoxazole, was screened against an additional 84 serotypes. It was found to be active against 64 of the serotypes, while 87 serotypes were sensitive to 2 at <3 mu g/mL. On comparison of the active serotypes, 6s exhibited greater potency versus 2. Analogs 6a-c,s were examined for in vitro metabolic stability by monkey liver microsomal assay. These analogs exhibited a greater than 7-fold improvement (t(1/2) > 200 min) in metabolic stability compared with 2 (t(1/2) > 27 min).

  DOI：

  10.1021/jm00014a029

文献信息

• [(Biaryloxy)alkyl]isoxazoles: Picornavirus Inhibitors
  作者：Joseph W. Guiles、Guy D. Diana、Daniel C. Pevear

  DOI：10.1021/jm00014a029

  日期：1995.7

  A series of biphenyl analogs, 6, of 5-[5-(2,6-dichloro-5-oxazolylphenoxy)pentyl]-3-methylisoxazole (2) have been synthesized and tested in vitro against 10 human rhinovirus serotypes in a TCID50 assay. The most potent compound in the series 6s, 3-[3-[2,6-dimethyl-4-(4-fluorophenyl)phenoxy]propyl]-3-methylisoxazole, was screened against an additional 84 serotypes. It was found to be active against 64 of the serotypes, while 87 serotypes were sensitive to 2 at <3 mu g/mL. On comparison of the active serotypes, 6s exhibited greater potency versus 2. Analogs 6a-c,s were examined for in vitro metabolic stability by monkey liver microsomal assay. These analogs exhibited a greater than 7-fold improvement (t(1/2) > 200 min) in metabolic stability compared with 2 (t(1/2) > 27 min).